Anti-GD2 monoclonal antibody 3F8 is under investigation in clinical trial NCT00089258 (Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.